Mapping naso-ocular symptom scores to EQ-5D-5L utility values in Japanese cedar pollinosis

Kumanomidou, Hiroshi; Kanai, Kazuaki; Oka, Aiko; Tamano, Haruna; Hirata, Yuji; Makihara, Seiichiro; Higaki, Toru; Akamatsu, Maki; Okamoto, Yoshitaka; Ikeda, Shunya; Okano, Mitsuhiro

doi:10.1016/j.alit.2021.11.002

Cited by 5 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the EQ-5D-5L has a validated translated version in the Malay language, locally validated [ 37 ]. Furthermore, it aligns well with the naso-ocular symptom severity experienced by allergic rhinitis patients and is considered valid and suitable for adaptation in this study [ 35 ].…”

Section: Discussionmentioning

confidence: 86%

“…A study mapping the naso-ocular symptom scores to the EuroQoL 5-Dimensions, 5-Levels (EQ-5D-5L) utility values was referred to estimate the sample size required to compare patients’ QoL between two groups. The EQ-5D-5L utility values in mean and standard deviation are corresponding to the disease severity in allergic rhinitis patients, where the utility values of 1.000 ± 0.000, 0.943 ± 0.085, 0.909 ± 0.095, 0.849 0.142, and 0.767 ± 0.175 corresponding to none, mild, moderate, severe, and most severe groups were referred [ 35 ]. In this study, the intervention aims to improve the symptoms, if not totally absence of symptoms, at least the mild disease state.…”

Section: Methods: Participants Interventions and Outcomesmentioning

confidence: 99%

“…The EQ-5D-5L, adapted for this study, will be used in allergic rhinitis-related studies [ 35 , 40 ]. The EQ-5D-5L consists of a descriptive system and the EQ VAS.…”

Section: Randomizationmentioning

confidence: 99%

See 2 more Smart Citations

The effectiveness of pharmacist-led educational model in adult patients with allergic rhinitis: a single-center randomized control trial protocol (AR-PRISE RCT)

Chew,

Lim,

Letchumanan

et al. 2024

Trials

View full text Add to dashboard Cite

Background Allergic rhinitis is a chronic respiratory disorder that significantly impacts patients’ quality of life (QoL) and work performance. Pharmacists are recognized as suitable professionals to provide patient education and pharmaceutical care for managing allergic rhinitis patients. However, local clinical practice guidelines, particularly regarding pharmaceutical care in public healthcare institutions, are lacking. This study protocol outlines a randomized controlled trial (RCT) designed to evaluate the effectiveness of a pharmacist-led educational model (AR-PRISE Model) in managing allergic rhinitis in adult patients compared to standard pharmaceutical care. The AR-PRISE model delivers patient educational material and a pharmaceutical care algorithm. Method This is a 6-month, single-center, prospective, randomized, two-arm, and parallel-group controlled trial. The trial recruits patients attending the otorhinolaryngology clinics of a tertiary referral hospital. Participants are randomized into control or intervention groups in a 1:1 ratio using permuted block randomization. The total number of participants estimated is 154, with each group requiring 77 participants. The control group receives standard pharmaceutical care, while the intervention group receives pharmacist-led education according to the AR-PRISE model. Both groups are assessed for middle turbinate endoscopy findings, disease severity, knowledge level, symptom control, medication adherence, and QoL at baseline and the end-of-study follow-up (day 180 ± 7). Depending on feasibility, intermediate follow-ups are conducted on days 60 ± 7 and 120 ± 7, either virtually or face-to-face. During intermediate follow-ups, participants are assessed for symptom control, medication adherence, and QoL. The intention-to-treat analysis includes all participants assigned to each group. An independent T-test compares the mean difference in knowledge level between the two groups. A two-way repeated measures ANOVA analysis is employed to determine between-group differences for scores of symptom control, adherence rate, and QoL. A P-value < 0.05 is considered statistically significant. Discussion This study protocol will provide a framework for conducting a randomized controlled trial (RCT) to evaluate the effectiveness of pharmacist-led education intervention in managing allergic rhinitis within public healthcare settings. The parameters measured in this trial will quantify outcomes associated with improvements in symptoms and QoL. By systematically assessing these outcomes, we aim to contribute valuable insights into the role of pharmacist-led interventions in enhancing the management of allergic rhinitis in public healthcare settings. Trial registration ClinicalTrials.gov NCT06027736. Registered on 9 July 2023—retrospectively registered.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Methods: Participants Interventions and Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

The effectiveness of pharmacist-led educational model in adult patients with allergic rhinitis: a single-center randomized control trial protocol (AR-PRISE RCT)

Chew,

Lim,

Letchumanan

et al. 2024

Trials

View full text Add to dashboard Cite

show abstract

“…When utilities were elicited with the standard gamble technique, severe itchy eyes were rated by US patients as the least preferred AR symptom (CoE = low). By contrast, Kumanomidou 27 found that higher severity of nasal symptoms (nasal congestion, sneezing, and rhinorrhea) displayed a stronger correlation with utility values than ocular symptoms (itchy eyes, watery/teary eyes). Tamayama 33 reported that patients with AR and current nasal symptoms had nonsignificantly higher utilities than those without current nasal symptoms (CoE = low).…”

Section: Utility Studiesmentioning

confidence: 88%

Patients' values and preferences for health states in allergic rhinitis—An artificial intelligence supported systematic review

Brozek,

Borowiack,

Sadowska

et al. 2024

Allergy

View full text Add to dashboard Cite

BackgroundAllergic rhinitis (AR) impacts patients' physical and emotional well‐being. Assessing patients' values and preferences (V&P) related to AR is an essential part of patient‐centered care and of the guideline development process. We aimed to systematically summarize the information about patients' V&P on AR and its symptoms and impact on daily life.MethodsWe conducted systematic review in a MEDLINE, Embase, PsychInfo, and CINAHL databases. We included studies which quantitatively assessed patients' V&P for specific outcomes in AR by assessing utilities, applying discrete choice approaches, or rating and ranking outcomes. We grouped outcomes as AR symptoms, functional status, and care‐related patient experience. Study selection and data extraction were supported by the Laser AI tool. We rated the certainty of evidence (CoE) using the GRADE approach.ResultsThirty‐six studies (41 records) were included: nine utility studies, seven direct‐choice studies and 21 studies of rating or ranking outcomes. Utilities were lower with increased AR severity and with the concomitant presence of asthma, but not with whether AR was seasonal or perennial (CoE = low–high). Patients rated AR symptom‐related outcomes as more important than those related to care‐related patient experience and functional status (CoE = very low–moderate). Nasal symptoms (mainly nasal congestion) followed by breathing disorders, general and ocular symptoms were rated as the symptoms with the highest impact.ConclusionsThis systematic review provides a comprehensive overview of V&P of patients with AR. Patients generally considered nasal symptoms as the most important. Future studies with standardized methods are needed to provide more information on V&P in AR.

show abstract

“…Ideally, an examination of all SGAs approved in Japan using TNSS would yield more reliable and robust conclusions as TNSS can be converted to QALY based on Japanese people's utility. 30 Second, this study included data from randomized double-blind trials involving Japanese patients with PAR, which might not be suitable for global interpretation of the results. Ideally, a network meta-analysis should be conducted before performing pharmacoeconomic studies.…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness Analysis of Second-Generation Antihistamine 1 Receptor Blockers and Japanese Kampo Shoseiryuto for Treating Perennial Allergic Rhinitis in Outpatient Settings in Japan

Nakagawa,

Kashiwabara,

Egawa

et al. 2024

Hosp Pharm

View full text Add to dashboard Cite

Objectives: Perennial allergic rhinitis (PAR) is common in Japan. Second-generation antihistamines (SGAs) are commonly used for its treatment; however, it remains unclear which SGA is the most cost-effective. Additionally, the pharmacoeconomics of Japanese Kampo shoseiryuto (which was traditionally prescribed to treat PAR in Japan) remains poorly understood. In this study, we aimed to investigate the effectiveness of various SGAs and shoseiryuto for the treatment of PAR in Japanese outpatients, from the healthcare payer’s perspective. Methods: The most cost- and clinically effective SGAs were determined from a list of 6 SGAs (bepotastine, 10 mg; cetirizine, 10 mg; ebastine, 10 mg; epinastine, 20 mg; loratadine, 10 mg; and olopatadine, 5 mg) together with shoseiryuto, using the overall improvement rate through a model-based analysis. The time horizon was 28 days. Costs were determined based on the Medical Fee Index in 2020. Deterministic and probabilistic sensitivity analyses were conducted to address the uncertainty of the base-case results. Results: Overall, bepotastine (10 mg) and ebastine (10 mg) were cost-effective. Shoseiryuto was less cost-effective than ebastine (10 mg) (dominated). Ebastine (10 mg) was the most cost-effective option based on deterministic and probabilistic sensitivity analyses. Conclusions: Ebastine (10 mg) was the most cost-effective treatment strategy for PAR among the agents evaluated in this study. This insight could aid in establishing an appropriate formulary for treating PAR in hospitals and communities.

show abstract

Mapping naso-ocular symptom scores to EQ-5D-5L utility values in Japanese cedar pollinosis

Cited by 5 publications

References 27 publications

The effectiveness of pharmacist-led educational model in adult patients with allergic rhinitis: a single-center randomized control trial protocol (AR-PRISE RCT)

The effectiveness of pharmacist-led educational model in adult patients with allergic rhinitis: a single-center randomized control trial protocol (AR-PRISE RCT)

Patients' values and preferences for health states in allergic rhinitis—An artificial intelligence supported systematic review

Cost-effectiveness Analysis of Second-Generation Antihistamine 1 Receptor Blockers and Japanese Kampo Shoseiryuto for Treating Perennial Allergic Rhinitis in Outpatient Settings in Japan

Contact Info

Product

Resources

About